Drug Profile
Cancer gene therapy - Cell Genesys/LICR
Alternative Names: Angiogenesis inhibibitor gene therapyLatest Information Update: 16 Oct 2006
Price :
$50
*
At a glance
- Originator Ludwig Institute for Cancer Research
- Class Antineoplastics; Gene therapies
- Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Oct 2006 Discontinued for Cancer in USA (unspecified route)
- 15 Aug 2003 unspecified for Cancer in USA (unspecified route)